

FULL-YEAR 2020 RESULTS

SANOFI  Empowering Life



“ I am incredibly proud of the measurable progress we made in 2020 even in the face of a global pandemic. We'll stay the course in 2021, focused on bringing breakthrough medicines and vaccines to people around the world. ”

PAUL HUDSON

CHIEF EXECUTIVE OFFICER, SANOFI

COMPANY SALES & BUSINESS EPS*

FULL-YEAR 2020 COMPANY SALES*

€36,041M

+3.3% (-0.2%)

FULL-YEAR 2020 BUSINESS EPS*

€5.86

+9.2% (+3.9%)

*Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.

€10,954M

Specialty Care

€5,973M

Vaccines

SALES BY GLOBAL BUSINESS UNIT

€14,720M

General Medicines

€4,394M

Consumer Healthcare

SALES BY GEOGRAPHY

U.S

€13,465M

EUROPE

€9,151M



REST OF THE WORLD

€13,425M

of which:

China **€2,454M**
Japan **€1,735M**
Brazil **€836M**
Russia **€641M**

SUCCESSFUL EXECUTION OF SANOFI'S PLAY TO WIN STRATEGY



Strong contribution to growth of innovative medicine for type 2 inflammation diseases



Record year for influenza vaccines



Strengthened R&D pipeline, especially in oncology, inflammation and immunology



Reinvesting savings to boost growth and pipeline

For further information on full-year 2020 results and definitions of financial indicators, please refer to the press release issued on February 05, 2021 at:

<https://www.sanofi.com/en/investors>



Sanofi.com



@Sanofi



Sanofi



@Sanofi

Sanofi.us



@SanofiUS



SanofiUS